Prophylactic Sclerotherapy of Large Esophageal Varices

Bret A. Lashner; Ira M. Hanan; Meir Stampfer; S. W. Hosking; A. G. Johnson; Harry Snady; Paolo Paoluzi; Antonio Pietroiusti; William C. Santangelo; Maria I. Dueno; Boyce L. Estes; Guenter J. Krejs

doi:10.1056/NEJM198810133191513

Prophylactic Sclerotherapy of Large Esophageal Varices

Bret A. Lashner, Ira M. Hanan, Meir Stampfer, S. W. Hosking, A. G. Johnson, Harry Snady, Paolo Paoluzi, Antonio Pietroiusti, William C. Santangelo, Maria I. Dueno, Boyce L. Estes, Guenter J. Krejs

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Abstract

To the Editor: In the article on prophylactic sclerotherapy (March 31 issue),¹ it may be true that sclerotherapy had no effect, but Santangelo et al. have not adequately eliminated the possibility that a Type II error accounted for the negative results. We must take exception to the calculations of the authors regarding the power of the study. In the Methods section of their article they state that 74 patients would be required to demonstrate a 50 percent reduction in the bleeding rate with sclerotherapy, assuming that 40 percent of the patients in the control group bled — a statistical power.

Original language	English (US)
Pages (from-to)	1015-1017
Number of pages	3
Journal	New England Journal of Medicine
Volume	319
Issue number	15
DOIs	https://doi.org/10.1056/NEJM198810133191513
State	Published - Oct 13 1988

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM198810133191513

Cite this

@article{a9657f295a014c3184cd4b9c9376a7fe,

title = "Prophylactic Sclerotherapy of Large Esophageal Varices",

abstract = "To the Editor: In the article on prophylactic sclerotherapy (March 31 issue),1 it may be true that sclerotherapy had no effect, but Santangelo et al. have not adequately eliminated the possibility that a Type II error accounted for the negative results. We must take exception to the calculations of the authors regarding the power of the study. In the Methods section of their article they state that 74 patients would be required to demonstrate a 50 percent reduction in the bleeding rate with sclerotherapy, assuming that 40 percent of the patients in the control group bled — a statistical power.",

author = "Lashner, {Bret A.} and Hanan, {Ira M.} and Meir Stampfer and Hosking, {S. W.} and Johnson, {A. G.} and Harry Snady and Paolo Paoluzi and Antonio Pietroiusti and Santangelo, {William C.} and Dueno, {Maria I.} and Estes, {Boyce L.} and Krejs, {Guenter J.}",

year = "1988",

month = oct,

day = "13",

doi = "10.1056/NEJM198810133191513",

language = "English (US)",

volume = "319",

pages = "1015--1017",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "15",

}

TY - JOUR

T1 - Prophylactic Sclerotherapy of Large Esophageal Varices

AU - Lashner, Bret A.

AU - Hanan, Ira M.

AU - Stampfer, Meir

AU - Hosking, S. W.

AU - Johnson, A. G.

AU - Snady, Harry

AU - Paoluzi, Paolo

AU - Pietroiusti, Antonio

AU - Santangelo, William C.

AU - Dueno, Maria I.

AU - Estes, Boyce L.

AU - Krejs, Guenter J.

PY - 1988/10/13

Y1 - 1988/10/13

N2 - To the Editor: In the article on prophylactic sclerotherapy (March 31 issue),1 it may be true that sclerotherapy had no effect, but Santangelo et al. have not adequately eliminated the possibility that a Type II error accounted for the negative results. We must take exception to the calculations of the authors regarding the power of the study. In the Methods section of their article they state that 74 patients would be required to demonstrate a 50 percent reduction in the bleeding rate with sclerotherapy, assuming that 40 percent of the patients in the control group bled — a statistical power.

AB - To the Editor: In the article on prophylactic sclerotherapy (March 31 issue),1 it may be true that sclerotherapy had no effect, but Santangelo et al. have not adequately eliminated the possibility that a Type II error accounted for the negative results. We must take exception to the calculations of the authors regarding the power of the study. In the Methods section of their article they state that 74 patients would be required to demonstrate a 50 percent reduction in the bleeding rate with sclerotherapy, assuming that 40 percent of the patients in the control group bled — a statistical power.

UR - http://www.scopus.com/inward/record.url?scp=0023784487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023784487&partnerID=8YFLogxK

U2 - 10.1056/NEJM198810133191513

DO - 10.1056/NEJM198810133191513

M3 - Letter

C2 - 3047579

AN - SCOPUS:0023784487

SN - 0028-4793

VL - 319

SP - 1015

EP - 1017

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 15

ER -

Prophylactic Sclerotherapy of Large Esophageal Varices

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this